From Momenta's Q3/2016 reporting: "A district court trial challenging four of Teva's five Orange Book-listed patents for COPAXONE 40 mg (glatiramer acetate injection) concluded on October 6, 2016. The Company expects a decision to be issued in the first quarter of 2017." The case which was filed on December 19 relates to the fifth Orange Book patent.
Market Data 
Markets 
AI
